Search results for "InAs"

showing 10 items of 4155 documents

Oridonin Targets Multiple Drug-Resistant Tumor Cells as Determined by in Silico and in Vitro Analyses

2018

Drug resistance is one of the main reasons of chemotherapy failure. Therefore, overcoming drug resistance is an invaluable approach to identify novel anticancer drugs that have the potential to bypass or overcome resistance to established drugs and to substantially increase life span of cancer patients for effective chemotherapy. Oridonin is a cytotoxic diterpenoid isolated from Rabdosia rubescens with in vivo anticancer activity. In the present study, we evaluated the cytotoxicity of oridonin toward a panel of drug-resistant cancer cells overexpressing ABCB1, ABCG2, or ΔEGFR or with a knockout deletion of TP53. Interestingly, oridonin revealed lower degree of resistance than the control dr…

0301 basic medicineDrug resistancenatural compound03 medical and health sciences0302 clinical medicineIn vivomedicinePharmacology (medical)DoxorubicinProtein kinase BPI3K/AKT/mTOR pathwayOriginal ResearchPharmacologydrug resistanceChemistrylcsh:RM1-950molecular dockingmolecular dynamics030104 developmental biologylcsh:Therapeutics. PharmacologyDocking (molecular)030220 oncology & carcinogenesisPharmacogenomicsCancer cellCancer researchmicroarraymedicine.drugcluster analysisFrontiers in Pharmacology
researchProduct

The emergence of drug resistance to targeted cancer therapies: Clinical evidence.

2019

For many decades classical anti-tumor therapies included chemotherapy, radiation and surgery; however, in the last two decades, following the identification of the genomic drivers and main hallmarks of cancer, the introduction of therapies that target specific tumor-promoting oncogenic or non-oncogenic pathways, has revolutionized cancer therapeutics. Despite the significant progress in cancer therapy, clinical oncologists are often facing the primary impediment of anticancer drug resistance, as many cancer patients display either intrinsic chemoresistance from the very beginning of the therapy or after initial responses and upon repeated drug treatment cycles, acquired drug resistance deve…

0301 basic medicineDrugCancer Researchmedicine.drug_classmedicine.medical_treatmentmedia_common.quotation_subjectTranslational researchApoptosisDrug resistanceMonoclonal antibodyBioinformatics03 medical and health sciences0302 clinical medicineNeoplasmsmedicineHumansPharmacology (medical)Hedgehog ProteinsEpigeneticsProtein Kinase Inhibitorsmedia_commonPharmacologyChemotherapybusiness.industryCancerImmunotherapyProtein-Tyrosine Kinasesmedicine.disease030104 developmental biologyInfectious DiseasesOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisbusinessProteasome InhibitorsDrug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
researchProduct

Exercise training as a drug to treat age associated frailty

2016

Exercise causes an increase in the production of free radicals [1]. As a result of a hormetic mechanism antioxidant enzymes are synthesised and the cells are protected against further oxidative stress. Thus, exercise can be considered as an antioxidant [2]. Age-associated frailty is a major medical and social concern as it can easily lead to dependency. In this review we describe that oxidative stress is associated with frailty and the mechanism by which exercise prevents age-associated frailty. We propose that individually tailored multicomponent exercise programmes are one of the best ways to prevent and to treat age-associated frailty.

0301 basic medicineDrugGerontologyAgingmedicine.medical_specialtyRos signallingFree Radicalsmedia_common.quotation_subjectmedicine.disease_causeBiochemistry03 medical and health sciencesPhysiology (medical)HumansMedicineIntensive care medicineExercisemedia_commonFrailtybusiness.industryMechanism (biology)TOR Serine-Threonine KinasesHormesisMitochondriaOxidative Stress030104 developmental biologybusinessOxidative stressFree Radical Biology and Medicine
researchProduct

Kinase Inhibitors in Multitargeted Cancer Therapy

2017

The old-fashioned anticancer approaches, aiming in arresting cancer cell proliferation interfering with non-specific targets (e.g. DNA), have been replaced, in the last decades, by more specific target oriented ones. Nonetheless, single-target approaches have not always led to optimal outcomes because, for its complexity, cancer needs to be tackled at various levels by modulation of several targets. Although at present, combinations of individual single-target drugs represent the most clinically practiced therapeutic approaches, the modulation of multiple proteins by a single drug, in accordance with the polypharmacological strategy, has become more and more appealing. In the perspective of…

0301 basic medicineDrugNiacinamideIndolesPyridinesmedia_common.quotation_subjectPharmacologyBioinformaticsBiochemistryReceptor tyrosine kinase03 medical and health sciencesCrizotinibPiperidinesMultitargeted drugs anticancer agents polypharmacology tyrosine kinase receptors oncogene addiction tumor microenvironment FDA-approved drugsNeoplasmsDrug DiscoverymedicineSunitinibHumansAnilidesPyrrolesProtein Kinase Inhibitorsmedia_commonPharmacologyTumor microenvironmentbiologybusiness.industryPhenylurea CompoundsOrganic ChemistryImidazolesCancerReceptor Protein-Tyrosine KinasesSorafenibmedicine.diseaseOncogene AddictionSettore CHIM/08 - Chimica FarmaceuticaClinical trialPyridazines030104 developmental biologyMechanism of actionbiology.proteinImatinib MesylateQuinazolinesMolecular MedicinePyrazolesmedicine.symptombusinessTyrosine kinase
researchProduct

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective.

2020

International audience; Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug targets which have been studied intensively in the past few decades. Although several drugs have been approved in this field, they are still limited to a subset of hematological malignancies (in particular T-cell lymphomas), with therapeutic potential not fully realized and the drug-resistance occurred after a certain period of use. To maximize the therapeutic potential of these classes of anticancer drugs, and to extend their application to solid tumors, numerous combination therapies containing an HDACi and an anticancer agent from other mechanisms are currently ongoing in clin…

0301 basic medicineDual targeting[SDV]Life Sciences [q-bio]Cancer therapyKinasesAntineoplastic AgentsBioinformaticsBiochemistryAnticancer drugsSynergistic effectsHistone Deacetylases03 medical and health sciences0302 clinical medicineDrug Delivery SystemsNeoplasmsReceptorsmedicineAnimalsHumansEpigeneticsPharmacologybiologybusiness.industryCancerDUAL (cognitive architecture)medicine.diseaseAnticancer drug3. Good healthEnzymesClinical trial[SDV] Life Sciences [q-bio]Histone Deacetylase Inhibitors030104 developmental biologyHistone030220 oncology & carcinogenesisbiology.proteinHistone deacetylases (HDACs)EpigeneticsDual inhibitorbusinessBiochemical pharmacology
researchProduct

Early ERK1/2 activation promotes DRP1-dependent mitochondrial fission necessary for cell reprogramming.

2016

During the process of reprogramming to induced pluripotent stem (iPS) cells, somatic cells switch from oxidative to glycolytic metabolism, a transition associated with profound mitochondrial reorganization. Neither the importance of mitochondrial remodelling for cell reprogramming, nor the molecular mechanisms controlling this process are well understood. Here, we show that an early wave of mitochondrial fragmentation occurs upon expression of reprogramming factors. Reprogramming-induced mitochondrial fission is associated with a minor decrease in mitochondrial mass but not with mitophagy. The pro-fission factor Drp1 is phosphorylated early in reprogramming, and its knockdown and inhibition…

0301 basic medicineDynaminsSomatic cellMAP Kinase Signaling SystemScienceCèl·lulesCellInduced Pluripotent Stem CellsKruppel-Like Transcription FactorsGeneral Physics and AstronomyBiologyMitochondrionMitochondrial DynamicsGeneral Biochemistry Genetics and Molecular BiologyMitocondrisArticleCell LineProto-Oncogene Proteins c-myc03 medical and health sciencesKruppel-Like Factor 4MiceMitophagymedicineAnimalsPhosphorylationInduced pluripotent stem cellGeneticsMultidisciplinarySOXB1 Transcription FactorsQGeneral ChemistryCellular ReprogrammingCell biologyMitochondria030104 developmental biologymedicine.anatomical_structurePhosphorylationMitochondrial fissionReprogrammingOctamer Transcription Factor-3Nature communications
researchProduct

Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma

2021

The molecular pathways which promote lung cancer cell features have been broadly explored, leading to significant improvement in prognostic and diagnostic strategies. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have dramatically altered the treatment approach for patients with metastatic non-small cell lung cancer (NSCLC). Latest investigations by using next-generation sequencing (NGS) have shown that other oncogenic driver mutations, believed mutually exclusive for decades, could coexist in EGFR-mutated NSCLC patients. However, the exact clinical and pathological role of concomitant genomic aberrations needs to be investigated. In this systematic review, we ai…

0301 basic medicineEGFRNSCLC03 medical and health sciences0302 clinical medicinesystematic reviewPathologyRB1-214MedicineEpidermal growth factor receptorLung cancerPathologicalbiologybusiness.industrymedicine.diseaserespiratory tract diseasesconcurrent genomic alterationCritical appraisal030104 developmental biologyLung cancer cellconcurrent genomic alterationsNGS030220 oncology & carcinogenesisConcomitantCancer researchbiology.proteinNon small cellbusinessTyrosine kinase<i>EGFR</i>Journal of Molecular Pathology
researchProduct

A Pharmacological Update of Ellagic Acid.

2018

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.thieme-connect.com/products/ejournals/pdf/10.1055/a-0633-9492.pdf This is a pre-print of an article published in Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093. The final authenticated version is available online at: https://doi.org/10.1055/a-0633-9492 Este es el pre-print del siguiente artículo Ríos, JL., Giner, RM., Marín, M. and Recio, MC. (2018). A pharmacological update of ellagic acid. Planta Medica, vol. 84, n. 15, pp. 1068-1093 que se ha publicado de forma definitiva en https://doi.org/10…

0301 basic medicineEllagic acid - Pharmacokinetics.Antioxidantmedicine.medical_treatmentMetaboliteInterleukin-1betaAnti-Inflammatory AgentsPharmaceutical ScienceApoptosisPharmacologyProtective AgentsProteína quinasa.NeuroprotectionAntioxidantsAnalytical Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEllagic AcidGlycationDrug DiscoverymedicineHumansProtein kinases.Cell ProliferationPharmacologyMetabolic SyndromeAldose reductaseInterleukin-6Tumor Necrosis Factor-alphaMetabolismo - Trastornos.Organic ChemistryNF-kappa BLipid metabolismAtherosclerosisEllagic acid - Physiological effect.NeuroprotectionMetabolism disorder030104 developmental biologyComplementary and alternative medicinechemistryÁcido elágico - Efectos fisiológicos.Antioxidantes.Ácido elágico - Farmacocinética.030220 oncology & carcinogenesisMolecular MedicineMetabolism - Disorders.Antioxidants.Ellagic acidPlanta medica
researchProduct

Nickel toxicity in P. lividus embryos: Dose dependent effects and gene expression analysis.

2018

Abstract Many industrial activities release Nickel (Ni) in the environment with harmful effects for terrestrial and marine organisms. Despite many studies on the mechanisms of Ni toxicity are available, the understanding about its toxic effects on marine organisms is more limited. We used Paracentrotus lividus as a model to analyze the effects on the stress pathways in embryos continuously exposed to different Ni doses, ranging from 0.03 to 0.5 mM. We deeply examined the altered embryonic morphologies at 24 and 48 h after Ni exposure. Some different phenotypes have been classified, showing alterations at the expenses of the dorso-ventral axis as well as the skeleton and/or the pigment cells…

0301 basic medicineEmbryo NonmammalianPigment cellmRNASettore BIO/05 - ZoologiaEmbryonic DevelopmentGene ExpressionDevelopmentAquatic ScienceOceanographyParacentrotus lividus03 medical and health sciencesNickelGene expressionAnimalsInvertebrateProtein kinase AGeneSkeletonEchinodermbiologyAnimalChemistryStress responseEmbryoGeneral Medicinebiology.organism_classificationPollutionPhenotypeCell biologyHeavy metal030104 developmental biologyToxicityUnfolded protein responseParacentrotusParacentrotuWater Pollutants ChemicalMarine environmental research
researchProduct

Rapid degradation of ABCA1 protein following cAMP withdrawal and treatment with PKA inhibitor suggests ABCA1 is a short-lived protein primarily regul…

2020

Objectives: ATP-binding cassette transporter A1 (ABCA1) is a key player in the reverse cholesterol transport (RCT) and HDL biogenesis. Since RCT is compromised as a result of ABCA1 dysfunction in diabetic state, the objective of this study was to investigate the regulation of ABCA1 in a stably transfected 293 cells expressing ABCA1 under the control of cAMP response element. Methods: To delineate transcriptional and posttranscriptional regulation of ABCA1, 293 cells were stably transfected with the full length ABCA1 cDNA under the control of CMV promoter harboring cAMP response element. cAMP-mediated regulation of ABCA1 and cholesterol efflux were studied in the presence of 8-Br-cAMP and af…

0301 basic medicineEndocrinology Diabetes and MetabolismResponse elementABCA1030209 endocrinology & metabolismDiabeteProtein kinase03 medical and health sciences0302 clinical medicinecAMPpolycyclic compoundsInternal MedicineABCA1 GeneMedicinecardiovascular diseasesProtein kinase Abiologybusiness.industryReverse cholesterol transportHEK 293 cellsnutritional and metabolic diseaseshemic and immune systemsTransfectionCell biology030104 developmental biologyCell cultureABCA1biology.proteinlipids (amino acids peptides and proteins)Stably transfectedbusinessRegulationResearch ArticleJournal of Diabetes &amp; Metabolic Disorders
researchProduct